Valuation: Alligator Bioscience AB

Market Cap 26.51M 2.8M 2.42M 2.26M 2.08M 3.92M 266M 3.96M 10.39M 133M 10.5M 10.27M 444M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 26.51M 2.8M 2.42M 2.26M 2.08M 3.92M 266M 3.96M 10.39M 133M 10.5M 10.27M 444M EV / Sales 2026 *
0.66x
EV / Sales 2027 * 4.49x
Free-Float
75.08%
Yield 2026 *
-
Yield 2027 * -
1 day-99.99%
1 week+505.47%
Current month+505.47%
1 month+88.99%
3 months+50.66%
6 months+86.19%
Current year-0.28%
1 week 0.04
Extreme 0.0417
0.32
1 month 0.04
Extreme 0.0417
0.32
Current year 0.04
Extreme 0.0417
0.42
1 year 0.04
Extreme 0.0417
5.42
3 years 0.04
Extreme 0.0417
1,508
5 years 0.04
Extreme 0.0417
3,509.77
10 years 0.04
Extreme 0.0417
34,002.21
Manager TitleAgeSince
Chief Executive Officer 55 01/06/2021
Director of Finance/CFO 61 12/08/2024
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 01/06/2021
Director/Board Member 68 09/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-99.99%+505.47% - - 2.79M
+0.90%+0.21%-0.74%+13.87% 48B
+1.98%+7.31%+430.66%+532.17% 41.13B
+3.44%-2.84%+29.17%+8.81% 37.56B
+1.40%-0.89%+7.63%+61.93% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
-0.16%-4.02% - - 16.12B
+2.20%+2.94%+35.92%+127.15% 16.05B
+1.25%+1.69%+4.72%+18.26% 13.76B
+4.25%-9.28%-0.78%-35.46% 12.1B
Average -8.23%-2.15%+65.18%+96.44% 27.83B
Weighted average by Cap. +1.91%-1.29%+85.86%+120.78%

Financials

2026 *2027 *
Net sales 39.9M 4.21M 3.64M 3.4M 3.13M 5.9M 400M 5.96M 15.65M 200M 15.8M 15.45M 669M 5.9M 622K 538K 502K 462K 872K 59.18M 882K 2.31M 29.63M 2.34M 2.29M 98.89M
Net income -36.3M -3.83M -3.31M -3.09M -2.84M -5.36M -364M -5.43M -14.23M -182M -14.38M -14.06M -608M -69.9M -7.37M -6.38M -5.95M -5.47M -10.33M -701M -10.45M -27.41M -351M -27.68M -27.07M -1.17B
Net Debt - -
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change Volume
04/08/26 SEK 0.0428 -2.28% 5,000
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise